EPISODE · Mar 18, 2026 · 9 MIN
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda
What this episode covers
FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda
NOW PLAYING
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m